1<i>H</i>‐1,2,3‐Triazole tethered isatin‐moxifloxacin: Design, synthesis and in vitro anti‐mycobacterial evaluation

Jiang, Yanting; Qian, Ailin; Li, Yan

doi:10.1002/ardp.201900040

Cited by 15 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yan and his colleagues [47] synthesized a series of 1,2,3‐triazole‐based isatin‐moxifloxacin (MXF) hybrids with higher lipophilicity compared to the parent Moxifloxacin.…”

Section: Biological Assessment Of 123‐triazole Tethered Isatin Hybridsmentioning

confidence: 99%

A Comprehensive Review of the Diverse Spectrum Activity of 1,2,3‐Triazole‐linked Isatin Hybrids

Rohila,

Sebastian,

Ansari

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

Heterocyclic compounds containing 1,2,3‐triazole and isatin as core structures have emerged as promising drug candidates due to their diverse biological activities such as anti‐cancer, antifungal, antimicrobial, antitumor, anti‐epileptic, antiviral, and more. The presence of 1,2,3‐triazoles and isatin heterocycles in these hybrids, both individually known for their medicinal significance, has increasingly piqued the interest of drug discovery researchers, as they seek to delve deeper into their extensive pharmacological potential for enhancing therapeutic efficacy. Moreover, these hybrid compounds are synthetically accessible using readily available materials. Therefore, there is a pressing need to provide a comprehensive overview of the existing knowledge in this field, offering valuable insights to readers and paving the way for the discovery of novel 1,2,3‐triazole‐linked isatin hybrids with therapeutic potential.

show abstract

“…Yan and his colleagues [47] synthesized a series of 1,2,3‐triazole‐based isatin‐moxifloxacin (MXF) hybrids with higher lipophilicity compared to the parent Moxifloxacin.…”

Section: Biological Assessment Of 123‐triazole Tethered Isatin Hybridsmentioning

confidence: 99%

A Comprehensive Review of the Diverse Spectrum Activity of 1,2,3‐Triazole‐linked Isatin Hybrids

Rohila,

Sebastian,

Ansari

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

show abstract

“…Moxifloxacin is also used to treat specific bacterial infections and drug-susceptible TB. [41,42] It inhibits the relaxation of supercoiled DNA and promotes the breakage of doublestranded DNA through restraining topoisomerase (DNA gyrase) enzymes. Through their antibacterial property, they have been identified as a beneficial candidate to treat TB.…”

Section: Levofloxacinmentioning

confidence: 99%

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

Reddy

Sinha

Kumar

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

The prevalence of tuberculosis (TB) remains the leading cause of death from a single infectious agent, ranking it above all other contagious diseases. The problem to tackle this disease seems to become even worse due to the outbreak of SARS-CoV-2.Further, the complications related to drug-resistant TB, prolonged treatment regimens, and synergy between TB and HIV are significant drawbacks. There are several drugs to treat TB, but there is still no rapid and accurate treatment available.Intensive research is, therefore, necessary to discover newer molecular analogs that can probably eliminate this disease within a short span. An increase in efficacy can be achieved through re-engineering old TB-drug families and repurposing known drugs.These two approaches have led to the production of newer classes of compounds with novel mechanisms to treat multidrug-resistant strains. With respect to this context, we discuss structural aspects of developing new anti-TB drugs as well as examine advances in TB drug discovery. It was found that the fluoroquinolone, oxazolidinone, and nitroimidazole classes of compounds have greater potential to be further explored for TB drug development. Most of the TB drug candidates in the clinical phase are modified versions of these classes of compounds. Therefore, here we anticipate that modification or repurposing of these classes of compounds has a higher probability to reach the clinical phase of drug development. The information provided will pave the way for researchers to design and identify newer molecular analogs for TB drug development and also broaden the scope of exploring future-generation potent, yet safer anti-TB drugs.

show abstract

“…There exist several isatin hybrid molecules generated by the combination of isatin moiety with other useful pharmacophores that have outstanding biological activities. Some of these hybrids include; Isatin-Azole hybrids [8][9][10]14,23,[33][34][35][36][37][38], Isatin-furan hybrids [9,18,33,35,39], Isatinthiophene hybrids [8,40], Isatin-indole hybrids [9,41], Isatin-fluoroquinolone hybrids [9,17,42], Isatin-Imine hybrids [9], Isatin-sulfonamide hybrids [2,9,21,43,44], Isatin-pyridine hybrids [45][46][47][48], Isatinchalcone hybrids [49], Isatin-quinazoline hybrids [50,51], Isatin-pthalazine hybrids [50], Isatinhydrazide hybrids [9,33,35,48], Isatin-naphthalene hybrids [14], isatin-thiosemicarbazone hybrid [9,20], Isatin-oxime hybrids [52], Isatin-nitrone hybrids…”

Section: Introductionmentioning

confidence: 99%

A Survey of Isatin Hybrids and their Biological Properties

Shu,

Eni,

Ntie-Kang

2024

Preprint

View full text Add to dashboard Cite

The emergence of diverse infections worldwide, which is a serious global threat to human existence, necessitate the urgent development of novel therapeutic candidates that can combat these diseases with efficacy. Isatin, a secondary metabolite from tryptophan is considered a privileged scaffold and favorable pharmacophore with a unique structural moiety and varied chemical and biological properties resulting in its widespread applications by medicinal chemists. Molecular hybridization is one of the most common and important techniques use in the synthesis of their bioactive hybrids in drug discovery. This review containing published articles from 2005 to 2022 focuses on isatin hybrids which have been synthesized and reported in the literature alongside a discussion on their biological properties. The purpose of this review is to set up the direction for the design and development of isatin-hybrids with tailored biological properties as effective therapeutic candidates inspired by nature.

show abstract

1H‐1,2,3‐Triazole tethered isatin‐moxifloxacin: Design, synthesis and in vitro anti‐mycobacterial evaluation

Cited by 15 publications

References 18 publications

A Comprehensive Review of the Diverse Spectrum Activity of 1,2,3‐Triazole‐linked Isatin Hybrids

A Comprehensive Review of the Diverse Spectrum Activity of 1,2,3‐Triazole‐linked Isatin Hybrids

Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery

A Survey of Isatin Hybrids and their Biological Properties

Contact Info

Product

Resources

About